Last $12.32 USD
Change Today +0.29 / 2.41%
Volume 40.3M
BSX On Other Exchanges
New York
As of 8:04 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - $14.08
52 Week Low
10/16/14 - $11.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

23,000 Employees
Last Reported Date: 02/26/14
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President of Global Operations...
Total Annual Compensation: $517.7K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Receives FDA and CE Mark Approval for New CoverEdge(TM) Surgical Leads for the Precision Spectra(TM) Spinal Cord Stimulator (SCS) System

Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) and CE Mark approval for the CoverEdge(TM) 32 and CoverEdge(TM) X 32 Surgical Leads. Designed for use with the Precision Spectra(TM) Spinal Cord Stimulator (SCS) System, the CoverEdge Surgical Leads are powered by the Illumina 3D(TM) Software, a proprietary, anatomy-based computer model for precise pain targeting. Boston Scientific is introducing the CoverEdge Surgical Leads at the Congress of Neurological Surgeons (CNS) this week in Boston. Previous surgical leads have delivered pain therapy with a maximum of 16 independent contacts. By offering 32 contacts -- each powered by a dedicated power source -- CoverEdge Surgical Leads are designed to deliver more focused coverage of the spinal cord for more pain relief. Available in two configurations, the CoverEdge 32 Surgical Lead features 32 tightly spaced contacts in four columns for precise pain targeting. The CoverEdge X 32 Surgical Lead offers the broadest span on the market among multi-column paddles. The combination of the CoverEdge Surgical Leads with the Precision Spectra SCS System and Illumina 3D Software is designed to deliver spinal cord stimulation in new ways.

Boston Scientific Corporation Initiates Study of Promus PREMIER(TM) Coronary Stent System in Underserved Patient Populations

Boston Scientific Corporation has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color. The Promus PREMIER Stent System is the company's latest durable polymer drug-eluting stent (DES) and is approved by the U.S. Food and Drug Administration (FDA) to treat coronary artery disease. Wayne Batchelor, M.D., F.A.C.C., F.S.C.A.I., and co-principal investigator, enrolled the first patient in the PLATINUM Diversity trial at Tallahassee Memorial Hospital, in Tallahassee, Florida. The PLATINUM Diversity trial is aligned with recent actions taken by the FDA, including implementation of FDASIA 907: Inclusion of Demographic Subgroups in Clinical Trials, and with the Boston Scientific Close the Gap education initiative which aims to promote health equity and ensure all patients receive optimal health care regardless of age, gender, race, ethnicity or primary language. The PLATINUM Diversity trial is an observational, prospective, multicenter, open-label, single-arm, post-approval study that will enroll up to 1,500 patients from understudied populations, specifically women, black Americans, Latinos/Hispanics, American Indians or Alaska Natives, at up to 65 sites in the U.S. The primary study endpoint is the rate of the composite of death, myocardial infarction and target vessel revascularization through 12 months. Initial data are expected to be available in 2016.

Kenneth J. Pucel to Leave Boston Scientific Corporation as Executive Vice President, Global Operations, Quality and Technology, Effective November 28, 2014

On September 29, 2014, Kenneth J. Pucel, Executive Vice President, Global Operations, Quality and Technology of Boston Scientific Corporation notified the company of his decision to leave the company effective November 28, 2014 in order to pursue another opportunity. Mr. Pucel will continue in his current capacity until that time and will assist in transitioning his responsibilities until his departure.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $12.32 USD +0.29

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $123.72 USD +0.41
Coloplast A/S kr475.80 DKK +8.80
Olympus Corp ¥3,665 JPY -35.00
St Jude Medical Inc $59.75 USD -0.24
Terumo Corp ¥2,417 JPY -22.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BSX Industry Range
Price/Earnings 67.2x
Price/Sales 2.2x
Price/Book 2.4x
Price/Cash Flow 24.0x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at